A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma Ltd.
UroGen Pharma Ltd.
Protara Therapeutics
Protara Therapeutics
Archivel Farma S.L.
Vaxiion Therapeutics
Viralytics
TheralaseĀ® Technologies Inc.
University of Kansas Medical Center
University of Lausanne Hospitals
BioCis Pharma Ltd
Halozyme Therapeutics